小剂量6542联合川芎嗪治疗糖尿病周围神经病变临床效果观察

doi:10.3969/j.issn.10073205.2019.05.006

河北医科大学学报

小剂量6542联合川芎嗪治疗糖尿病周围神经病变临床效果观察

1.华北石油中医医院内科，河北任丘 062552；2.河北医科大学第二医院内分泌科，河北石家庄 050000；3.华北石油中医医院中医科，河北任丘 062552

出版日期:2019-05-25 发布日期:2019-05-22
作者简介:罗妮娅（1979-），女，湖南常德人，华北石油中医医院主治医师，医学硕士，从事内分泌疾病诊治研究。

Clinical research for treatment of diabetic peripheral neuropathy by combination therapy with small doses of anisodamine injection and ligustrazine injection#br#

1.Department of Internal Medicine， Traditional Chinese Medical Hospital of Huabei Petroleum, Hebei #br# Province, Renqiu 062552, China； 2.Department of Endocrinology, the Second Hospital of Hebei Medical #br# University, Shijiazhuang 050000， China； 3.Department of Traditional Chinese Medicine， Traditional #br# Chinese Medical Hospital of Huabei Petroleum, Hebei Province, Renqiu 062552, China

Online:2019-05-25 Published:2019-05-22

摘要/Abstract

摘要： ［摘要］〓
〖HTH〗目的〖HTSS〗〖KG*2〗探讨小剂量6542注射液联合川芎嗪注射液治疗糖尿病周围神经病变患者的效果及安全性。
〖HTH〗方法〖HTSS〗〖KG*2〗选取糖尿病周围神经病变患者60例，随机分为对照组及治疗组各30例。对照组口服甲钴胺及依帕司他治疗，治疗组在对照组基础上应用小剂量6542注射液及川芎嗪注射液治疗，疗程均为2周。比较2组临床疗效，治疗前后检测超敏C反应蛋白（high sensitive C reaction protein，hsCRP) 水平，多伦多临床评分系统(Toronto Clinical Scoring System，TCSS)评分，双侧正中神经、腓总神经、胫神经的运动传导速度(motor nerve conduction velocity,MNCV)和正中神经、腓肠神经的感觉传导速度(sensory nerve conduction velocity,SNCV)。
〖HTH〗结果〖HTSS〗〖KG*2〗治疗后，2组hsCRP含量均明显低于治疗前，治疗组hsCRP含量明显低于对照组(P＜005)。2组正中神经MNCV、腓总神经MNCV、胫神经MNCV、正中神经SNCV、腓肠神经SNCV均明显高于治疗前，且治疗组腓总神经MNCV、胫神经MNCV、正中神经SNCV、腓肠神经SNCV均明显高于对照组(P＜005)。治疗组临床疗效优于对照组，总有效率高于对照组（P＜005）。2组TCSS评分均明显低于治疗前，治疗组TCSS评分低于对照组，差异有统计学意义(P＜005)。治疗组TCSS评分疗效优于对照组，总有效率明显高于对照组（P＜005）。
〖HTH〗结论〖HTSS〗〖KG*2〗小剂量6542联合川芎嗪治疗糖尿病周围神经病变是相对安全的，而且经济有效，特别对于基层患者在减少药费及社保费用支出等方面有实际的意义。

关键词: 糖尿病神经病变, 山莨菪碱, 川芎嗪

Abstract: ［Abstract］〓Objective〖HTSS〗〓To investigate the efficacy and safety of lowdose anisodamine injection combined with tetramethylpyrazine injection in the treatment of patients with diabetic neuropathies.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓Sixty patients with diabetic neuropathies were randomly divided into control group and treatment group, 30 cases in each group. The control group was treated with Mecobalamin and Epalrestat. The treatment group was treated with lowdose anisodamine and Tetramethylpyrazine injection in addition to the medicine used in the control group. The treatment lasted 2 weeks. The following data were used to compare the clinical efficacy of the two groups before and after treatment：the level of high sensitive C reaction protein(hsCRP); the score of the Toronto Clinical Scoring System(TCSS); the motor nerve conduction velocity(MNCV) of bilateral median nerve, common peroneal nerve, tibial nerve and the sensory nerve conduction velocity(SNCV) of median nerve, sural nerve.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓After treatment, the hsCRP levels in both groups were significantly lower than those before treatment, and the hsCRP levels in the treatment group were significantly lower than those in the control group(P＜005). In both groups, the MNCV data of median nerve, the common peroneal nerve, the radial nerve and median nerve and the sural nerve were significantly higher than those before treatment, and the MNCV date of common peroneal nerve, tibial nerve and the SNCV data of median nerve, sural nerve were higher than those of control group(P＜005). The clinical efficacy of the treatment group was better than that of the control group, and the total effective rate was higher than that of the control group(P＜005). The TCSS scores of the two groups were significantly lower than those before treatment. The TCSS scores of the treatment group were lower than the control group(P＜005). The TCSS score of the treatment group was better than that of the control group, and the total effective rate was significantly higher than that of the control group(P＜005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The treatment of diabetic neuropathies with lowdose anisodamine combined with tetramethylpyrazine is relatively safe and costeffective, especially for grassroots patients with primary disease who have practical clinical significance in reducing drug costs and social security expenses.

Key words: diabetic neuropathies, anisodamine, tetramethylpyrazine

罗妮娅1，张力辉2*，张成量1，袁〓娜1，刘树科3，阴〓丽1. 小剂量6542联合川芎嗪治疗糖尿病周围神经病变临床效果观察[J]. 河北医科大学学报, doi: 10.3969/j.issn.10073205.2019.05.006.

LUO Niya1， ZHANG Lihui2*， ZHANG Chengliang1, YUAN Na1, LIU Shuke3, YIN li1. Clinical research for treatment of diabetic peripheral neuropathy by combination therapy with small doses of anisodamine injection and ligustrazine injection#br#[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.10073205.2019.05.006.

[1]	张桐毓, 杨传慧, 徐宁. 糖尿病周围神经病变炎症因子变化及与神经传导速度相关性 [J]. 河北医科大学学报, 2023, 44(5): 517-520,571.
[2]	于冬, 温莉, 张涛, 郭妍, 金城, 孟现军. 2型糖尿病胫神经病变超声特征的ROC曲线分析[J]. 河北医科大学学报, 2021, 42(9): 1032-1036.
[3]	戚艳艳. 神经电生理指标与糖尿病周围神经病变病情分级的相关性分析[J]. 河北医科大学学报, 2019, 40(2): 161-164,168.
[4]	刘宪红1，靳妍霞1，牛金葆2，丰慧慧3，吴绍华4，孙秀全5. 高压氧联合普瑞巴林治疗痛性糖尿病周围神经病变的临床研究[J]. 河北医科大学学报, 2016, 37(11): 1246-1249.
[5]	李艳君;冯彦景;查月芳. 10g单丝在糖尿病周围神经病变筛查中的价值[J]. , 2015, 36(8): 884-884.
[6]	屈冬梅;汪青梅;赵海军;吴志华;尹丽娜;叶学奎. 654-2抢救产褥感染性冷休克时D-二聚体指标的变化[J]. , 2015, 36(6): 714-714.
[7]	李艳君;孙金昊(综述);冯彦景;路惠民(审校). 痛性糖尿病周围神经病变[J]. , 2014, 35(8): 986-986.
[8]	倪海霞;郭建东;赵海军. 硫辛酸联合甲钴胺对2型糖尿病心脏自主神经病变患者心率变异性的影响[J]. , 2014, 35(3): 312-312.
[9]	张艳町;牛久欣;张秋娅;张海丽;吴霞. α-硫辛酸与前列地尔、甲钴胺联合治疗糖尿病周围神经病变的临床研究[J]. , 2014, 35(2): 133-133.
[10]	韩瑞平;谷春芳. 硫辛酸对糖尿病周围神经病变的疗效观察[J]. , 2012, 33(9): 1056-1056.
[11]	邱轩. 糖尿病神经病变及神经性疼痛的治疗进展[J]. , 2012, 33(11): 1351-1351.
[12]	贺红霞. 高压氧与药物联合治疗美尼尔症疗效观察[J]. , 2011, 32(12): 1414-1414.
[13]	陈贵言;魏锋;孙迎俊;崔璐. 马来酸桂哌齐特联合甲钴胺治疗糖尿病周围神经病变临床观察[J]. , 2010, 31(4): 440-440.
[14]	姚福军;郑福禄;张重阳. 川芎嗪对急性重症胰腺炎胰腺细胞凋亡的影响[J]. , 2009, 30(6): 601-601.

小剂量6542联合川芎嗪治疗糖尿病周围神经病变临床效果观察

Clinical research for treatment of diabetic peripheral neuropathy by combination therapy with small doses of anisodamine injection and ligustrazine injection#br#

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价